Expert opinion on therapeutic patents · 2026
Overcoming the blood-brain barrier for therapeutics targeting neurodegenerative diseases: a patent review (2020-present).
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Huang Daowei, Lu Roujun, Tang Ruijing, Sun Jiarui, Sang Zhipei
Аннотация
INTRODUCTION: The blood-brain barrier (BBB) restricts drug entry into the CNS, with most therapeutics showing <1% brain penetration, limiting efficacy in neurodegenerative diseases.
AREAS COVERED: Patents (2020-2026) were retrieved from SciFinder, Web of Science, PubMed, and Reaxys using combinations of 'blood-brain barrier,' 'brain delivery,' and neurodegenerative disease terms. Technologies were included if supported by in vitro or in vivo BBB‑penetration evidence for neurodegenerative indications; purely computational, non‑English untranslated, and non‑targeted conventional formulation patents were excluded. Eligible patents were classified into protein/antibody‑based, small molecule, nanocarrier, physical‑assisted, permeability enhancer, and emerging technology categories.
EXPERT OPINION: Receptor-mediated transcytosis, dual-targeting ligands, and ultrasound opening are enhancing delivery precision; emerging systems (small molecules, peptides, nanozymes) combine penetration with target inhibition, overcoming traditional bottlenecks and accelerating clinical translation.
AREAS COVERED: Patents (2020-2026) were retrieved from SciFinder, Web of Science, PubMed, and Reaxys using combinations of 'blood-brain barrier,' 'brain delivery,' and neurodegenerative disease terms. Technologies were included if supported by in vitro or in vivo BBB‑penetration evidence for neurodegenerative indications; purely computational, non‑English untranslated, and non‑targeted conventional formulation patents were excluded. Eligible patents were classified into protein/antibody‑based, small molecule, nanocarrier, physical‑assisted, permeability enhancer, and emerging technology categories.
EXPERT OPINION: Receptor-mediated transcytosis, dual-targeting ligands, and ultrasound opening are enhancing delivery precision; emerging systems (small molecules, peptides, nanozymes) combine penetration with target inhibition, overcoming traditional bottlenecks and accelerating clinical translation.